Literature DB >> 1704431

Clinical and biologic effects of granulocyte colony stimulating factor in the treatment of myelokathexis.

B Weston1, R A Axtell, R F Todd, M Vincent, K J Balazovich, S J Suchard, L A Boxer.   

Abstract

Successful treatment of a patient with myelokathexis, a rare form of chronic neutropenia associated with recurrent infections, is described. Rapid mobilization of bone marrow neutrophils and improved myeloid morphologic features were observed after treatment with human granulocyte colony stimulating factor. Transient thrombocytopenia and bone pain were observed during treatment. Although neutrophil chemotaxis, superoxide production, and FcRIII surface expression were reduced, the patient improved clinically after restoration of a normal neutrophil count.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1704431     DOI： 10.1016/s0022-3476(05)80488-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  13 in total

Review 1.  Genetics on a WHIM.

Authors:  Omar Al Ustwani; Razelle Kurzrock; Meir Wetzler
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

Review 2.  Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.

Authors:  L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 3.  WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Authors:  Lauren E Heusinkveld; Shamik Majumdar; Ji-Liang Gao; David H McDermott; Philip M Murphy
Journal:  J Clin Immunol       Date:  2019-07-16       Impact factor: 8.317

Review 4.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

5.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

Review 6.  Infections in patients with inherited defects in phagocytic function.

Authors:  Timothy Andrews; Kathleen E Sullivan
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 7.  WHIM syndrome: congenital immune deficiency disease.

Authors:  Toshinao Kawai; Harry L Malech
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

8.  A report of WHIM syndrome (myelokathexis) - clinical features and bone marrow morphology.

Authors:  Flavio Augusto Naoum
Journal:  Rev Bras Hematol Hemoter       Date:  2011

9.  Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.

Authors:  Lauren E Heusinkveld; Erin Yim; Alexander Yang; Ari B Azani; Qian Liu; Ji-Liang Gao; David H McDermott; Philip M Murphy
Journal:  Expert Opin Orphan Drugs       Date:  2017-09-25       Impact factor: 0.694

Review 10.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.